Pegylacja - metoda zmiany właściwości leków polipeptydowych, substancji biologicznie aktywnych

• Autorzy: Ferenc J. , Kieć-Kononowicz K.

Warianty tytułu

EN

Pegylation - a method of modification of properties of polypeptidic drugs and biologically actiye compounds

• Języki publikacji: PL

Abstrakty

EN

This review attempts to briefly summarize the recent developments in the area of PEGylation. Pegylation, the process by which polyethylene glycol chains are attached to as well protein and peptide drugs as low molecular weight molecules is used to modify the properties of drugs, biologically active structures. It has influence on pharmacokinetic and pharmacodynamic properties, stability and immunogenicity of structures. The advantages and drawbacks of such modifications were discussed. Pegylation of polypeptide and protein structures as well as small molecules was presented. Pegylation process was divided in two groups: pegylation of the first and second generation. Both processes were presented. Examples of pegylated drugs (Adagen, Oncaspar - first generation; PEG-intron, Pegasys, Somavert, Neulasta - second generation) already introduced into the market were shortly presented, structures being under investigation were mentioned.

Słowa kluczowe

PL

biokoniugacja; pegylacja; leki pegylowane; białka pegylowane

EN

bioconjugation; PEGylation; pegylated drugs; pegylated proteins

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2005
• Tom: [Z] 59, 11-12
• Strony: 953--979
• Opis fizyczny: Bibliogr. 41 poz., schem., tab., wykr.

Twórcy

autor

Ferenc J.

• Katedra Technologii i Biotechnologii Środków Leczniczych, Collegium Medicum Uniwersytetu Jagiellońskiego, ul. Medyczna 9, 30-688 Kraków

autor

Kieć-Kononowicz K.

• Katedra Technologii i Biotechnologii Środków Leczniczych, Collegium Medicum Uniwersytetu Jagiellońskiego, ul. Medyczna 9, 30-688 Kraków

Bibliografia

• [1] G. Walsh. Biopharmaceuticals Biochemistry and Biotechnology, wyd. II, John Wiley & Sons. Chichester 2003.
• [2] W. Kreis. D. Baron, G. Stoli, Biotechnologie der Arzneistoffe, Deutscher Apotheker Yerlag. Stułtgart 2001.
• [3] T. Dingermann. Gentechnik Biotechnik, Wissenschaftliche Verlagsgesellschaft mbH. Stuttgart 1999.
• [4] O. Kayser. R. H. Muller, Pharmaceutical Biotechnology Drug Discovery m d Clinical Applications, Wiley-VCH Verlag GmbH & Co. KGaA 2004.
• [5] K. Kieć-Kononowicz, Biotechnologia, 2004, 66, 87.
• [6] K. Kieć-Kononowicz, Farmacja Polska, 2005, 61, 407.
• [7] F.M. Veronese, Adv. Drug Deliv. Rev., 2002, 54, 453.
• [8] J.M. Harris, R.B. Chess, Naturę Rev. Drug Discov., 2 0 0 3 ,2 ,2 1 4.
• [9] EF. Davis, Adv. Drug Deliv. Rev., 2002, 54, 457.
• [10] J.M. Harris, F.M. Veronese, Adv. Drug Deliv. Rev., 2003, 55, 1259.
• [11] J.M. Harris, N.E. Martin. M. Modi, Clin. Pharmacokinet., 2001, 40, 539.
• [12] R. Duncan, Nature Rev. Drug Discov., 2 0 03,3, 347.
• [13] F.M. Veronese, M. Morpurgo, II Farmaco, 1999, 54, 497.
• [14] C. Elvira, A. Gallardo, J.S. Roman, A. Cifuentes, Molecules, 2005, 10, 114.
• [15] M.J. Roberts, M.D. Bentley, J.M. Harris, Adv. Drug Deliv. Rev., 2002, 54, 459.
• [16] R. Mehvar, J. Pharm. Pharmaceut. Sci., 2000, 3, 125.
• [17] O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, C. Gegg, Adv. Drug Deliv. Rev., 2002, 54,477.
• [18] H. Sato, Adv. Drug Deliv. Rev., 2002,54, 487.
• [19] P. Caliceti, F.M. Veronese, Adv. Drug Deliv. Rev., 2003, 55, 1261.
• [20] R.K. Reddy, Ann. Pharmacother., 2000, 34, 915.
• [21] M.L. Graham, Adv. Drug Deliv. Rev., 2003, 55, 1293.
• [22] F.M. Veronese, Biomaterials, 2001, 22, 405.
• [23] A.M. Cantin, D.E. W oods,D. Cloutier, E.K. Dufour, R. Leduc, Am. J. Respir. Celi Mol. Biol., 2002. 27, 659.
• [24] H. Tsubery, M. Mironchik, M. Fridkin, Y. Shechter, J. Biol. Chem., 2004, 279, 38118.
• [25] S. Tsunoda, T. Ishikawa, Y. Yamamoto, H. Kamada, K. Koizumi, J. Matsui, Y. Tsutsumi, T. Hirano, T. Mayumi, J. Pharmacol. Exp. Ther., 1999, 290, 368.
• [26] Y-S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, D. F. Wyss, Adv. Drug Deliv. Rev., 2002, 54, 547.
• [27] D.E. Bakrr, Rev. Gastroenterol. Disord., 2001, 1, 87.
• [28] R.K. Reddy, M.W. Modi, S. Pedder. Adv. Drug Deliv. Rev., 2002, 54, 571.
• [29] C. Parkinson, J.A. Scarlett. P.J. Trainer. Adv. Drug Deliv. Rev., 2003, 55, 1303.
• [30] W.P. Petros, Phannacotherapy, 2003, 23, IS.
• [31] G. Molineux, Pharmacotherapy, 2003, 23, 3S.
• [32] R.B. Pepinsky, D.J. Lepage, A. Gili, A. Chakraborty, S. Vaidyanthan, M. Green. D.P. Baker, E. Whalley, P.S. Hochman, P. Martin, J. Pharmacol. Exp. Ther., 2001, 297, 1059.
• [33] P. Esposito, L. Barbero, P. Caccia, P. Caliceti, M. D’Antonio, G. Piquet, F.M. Veronese, Adv. Drug Deliv. Rev„ 2003, 55, 1279.
• [34] C.K. Edwards, S.W. Martin, J. Seely, O. Kinstler, S. Buckel, A.M. Bendele, M.E. Consenza. U. Feige, T. Kohno, Adv. Drug Deliv. Rev., 2003, 55, 1315.
• [35] R.W. Moreadith, D. Collen, Adv. Drug Deliv. Rev., 2003, 55, 1337.
• [36] K.D. Hinds, S.W. Kim, Adv. Drug Deliv. Rev., 2002, 54, 505.
• [37] A.W. Chapman, Adv. Drug Deliv. Rev., 2002, 54, 531.
• [38] F.M. Veronese. P. Caliceti, O. Schiavon. M. Sergi, Adv. Drug Deliv. Rev., 2002. 54. 58
• [39] M J. Grace, S. Lee, S. Bradshaw, J. Chapman, J. Spond. S. Cox, M DeLorenzo. D. Brassarj. D. Wylie, S. Cannon-Carlson, C. Cullen, S. Indelicato. M. Voloch, R. Bordens. J. Biol. Chem..2005, 280, 6327.
• [40] B.A. Kerwin, B.S. Chang, C.V. Gegg. M. Gonnelli, T. Li, G.B. Strambini. Protein Sci., 2002, 11.1825.
• [41] M. Zacchigna, G. Di Luca, F. Cateni, S. Zorzet, V. Maurich, II Farmaco 2003, 58, 1307.